Patricia Inácio, PhD,  science writer—

A Phase 2 trial designed to test a self-administered inhaled formulation of nitric oxide (NO) for adults with chronic obstructive pulmonary disease (COPD), or bronchiectasis, is recruiting eligible patients. The formulation, called RESP301, is a liquid solution that, once inhaled through a nebulizer, releases NO into the lungs. RESP301 was…

Verona Pharma has completed patient enrollment for ENHANCE-2, a Phase 3 clinical trial evaluating the safety and efficacy of ensifentrine, an inhalation therapy for chronic obstructive pulmonary disease (COPD). According to Verona, the trial exceeded its enrollment target of 800 participants, even amid the COVID-19 pandemic. Top-line data are…

Adults with chronic obstructive pulmonary disease (COPD) are being recruited for a study into whether Wellinks’ first integrated virtual management system solution for COPD can improve patient outcomes. The 24-week study is being conducted in partnership with the COPD Foundation, and it intends to enroll between 100…

Breathing exercises via a mobile app help improve respiratory muscle strength and mobility in the diaphragm in patients with severe chronic obstructive pulmonary disease (COPD), a study says. The study, “Respiratory muscle training program supplemented by a cell-phone application in COPD patients with severe airflow limitation,” was published…

Twenty years after the collapse the World Trade Center, rescue workers and volunteers who assisted at the site in the two days that immediately followed face a 30% increased risk of chronic obstructive pulmonary disease (COPD), researchers report. COPD in these first responders is often preceded by a diagnosis of…

Smaller particles and optimal inhalation speed of inhaler treatments — a mainstay for people with chronic obstructive pulmonary disease (COPD) — enhance their delivery to deep airway passages, a study shows. The study, “Computational evaluation of drug delivery in human respiratory tract under realistic inhalation,” was…

GoodRx, a platform for healthcare savings in the U.S., and pharmaceutical company Boehringer Ingelheim have teamed up to help lower out-of-pocket medication costs  for people with chronic obstructive pulmonary disease (COPD) or type 2 diabetes. Patients will be able to enroll in sponsored copay programs to access  Boehringer…

Treatment with mepolizumab, an antibody designed to lower the levels of eosinophils — immune cells linked with worse chronic obstructive pulmonary disease (COPD) — was found to reduce the annual rate of exacerbations and improve health-related quality of life in people with eosinophil-associated COPD. The findings, from a meta-analysis…

Approximately 40% of chronic obstructive pulmonary disease (COPD) patients in the U.S. — and notably, most of those living in small towns or rural areas — have limited access to pulmonary rehabilitation (PR) maintenance programs, according to a recent study. Indeed, roughly 17% of people with COPD from this…

Note: This story was updated May 21, 2021, as an earlier version of this article misidentified Renu Jain, PhD, scientific director of medical affairs at GlaxoSmithKline.  People with chronic obstructive pulmonary disease (COPD) who do not experience exacerbations, or flare-ups, within the previous 12 months are still at risk…